GlassScriptPhysician profile
Dawn P Bitgood
NPI 1437382942
$2,552.35
in general payments reported to CMS, 2019-2025
23 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $651 · 2023: $565 · 2024: $310 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $369.32 | 2021-2025 | Enhertu, Tagrisso |
| Pharmacyclics LLC, An Abbvie Company | $133.68 | 2022 | |
| Daiichi Sankyo INC. | $131.86 | 2021-2023 | Enhertu |
| Novo Nordisk INC | $127.21 | 2025 | Wegovy |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Kite Pharma, INC. | $124.53 | 2022 | |
| Deciphera Pharmaceuticals INC. | $124.30 | 2024 | Qinlock |
| Emd Serono, INC. | $117.77 | 2023 | Tepmetko |
| Eisai INC. | $117.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.56 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $107.13 | 2021 | |
| Janssen Biotech, INC. | $102.61 | 2025 | Carvykti, Rybrevant |
| Eusa Pharma (US) LLC | $100.00 | 2022 | |
| Astellas Pharma US INC | $99.99 | 2025 | |
| Springworks Therapeutics, INC. | $98.77 | 2025 | Ogsiveo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $94.87 | 2021 | |
| Lilly USA, LLC | $85.85 | 2025 | |
| Seagen INC. | $83.81 | 2023 | Tukysa |
| Recordati_rare_diseases_inc. | $81.98 | 2024 | Sylvant |
| Puma Biotechnology, INC. | $79.17 | 2022 | |
| Novocure INC. | $57.38 | 2024-2025 | Optune, Optune Gio |
| Mylan Specialty L.P. | $49.07 | 2024 | Yupelri |
| Boston Scientific Corporation | $24.85 | 2024 | Spaceoar Vue System - 10ml |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Bitgood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.